Advanced Cell Technology to Webcast 2013 Annual Shareholders’ Meeting on Tuesday, October 22nd
October 18 2013 - 12:01PM
Business Wire
Advanced Cell Technology, Inc. (“ACT”)(OTCBB: ACTC), a leader in
the field of regenerative medicine, announced today that it will
webcast its Annual Shareholders’ Meeting to be held on Tuesday,
October 22nd at the Hyatt Regency Suites, Palm Springs, 285 N. Palm
Canyon Drive, Palm Springs, Calif. The meeting is open to
shareholders of record as of August 23, 2013. The webcast will
begin at 9 a.m. PDT, after the Company completes the formal portion
of the meeting, where results of proxy voting will be announced. At
that time, members of the management team will deliver a Company
presentation and address questions from shareholders. Questions
will be taken from both members of the live audience as well as
electronically from the webcast.
The webcast will be available live and for replay by webcast at:
http://us.meeting-stream.com/advancedcelltechnology102213
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc., a biotechnology company, engages
in the development and commercialization of human embryonic and
adult stem cell technology in the field of regenerative medicine.
The company is conducting various clinical trials for treating
macular degeneration, and has a preclinical development pipeline
focused on products for eye diseases, autoimmune and inflammatory
diseases, and wound healing. Its intellectual property portfolio
includes pluripotent stem cell platforms comprising embryonic stem
cell and induced pluripotent stem cell (iPSC) platforms; and other
cell therapy research programs, such as opthamology,
autoimmune/inflammation, and platelet programs. Advanced Cell
Technology, Inc. develops and maintains an intellectual property
portfolio, with ownership or licensing of approximately 37 issued
patents and approximately 190 patent applications pending in the
field of regenerative medicine and stem cell therapy. The company
is headquartered in Marlborough, Massachusetts.
Forward-Looking Statements
Statements in this news release regarding future financial and
operating results, future growth in research and development
programs, potential applications of our technology, opportunities
for the company and any other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Any
statements that are not statements of historical fact (including
statements containing the words “will,” “believes,” “plans,”
“anticipates,” “expects,” “estimates,” and similar expressions)
should also be considered to be forward-looking statements. There
are a number of important factors that could cause actual results
or events to differ materially from those indicated by such
forward-looking statements, including: limited operating history,
need for future capital, risks inherent in the development and
commercialization of potential products, protection of our
intellectual property, and economic conditions generally.
Additional information on potential factors that could affect our
results and other risks and uncertainties are detailed from time to
time in the company’s periodic reports, including the report on
Form 10-K for the year ended December 31, 2012. Forward-looking
statements are based on the beliefs, opinions, and expectations of
the company’s management at the time they are made, and the company
does not assume any obligation to update its forward-looking
statements if those beliefs, opinions, expectations, or other
circumstances should change. Forward-looking statements are based
on the beliefs, opinions, and expectations of the company’s
management at the time they are made, and the company does not
assume any obligation to update its forward-looking statements if
those beliefs, opinions, expectations, or other circumstances
should change. There can be no assurance that the Company’s
clinical trials will be successful.
Investors:CEOcast, Inc.Robert Woods, 212-732-4300orPress:ACT
Corporate CommunicationsBill Douglass, 646-450-3615orRusso
PartnersMartina Schwarzkopf, Ph.D., 212-845-4292orBusiness
Development:Advanced Cell TechnologyMatthew Vincent, Ph.D.,
508-756-1212 x324mvincent@advancedcell.com